Citryll's Exciting Phase IIa Hidradenitis Suppurativa Trial
Citryll has just announced a significant milestone in its clinical research journey with the dosing of the first patient in its Phase IIa trial targeting hidradenitis suppurativa (HS), a chronic inflammatory disease affecting many individuals worldwide.
Understanding Hidradenitis Suppurativa
Hidradenitis suppurativa is a challenging condition characterized by painful nodules and abscesses that can severely affect patients’ quality of life. Affecting roughly 2% of the population in developed countries, the disease leads to uncomfortable skin lesions and scars that can be both physically and psychologically debilitating.
About the Phase IIa Trial
The trial, named "Citylights,” aims to evaluate the efficacy, safety, and tolerability of CIT-013, a first-in-class monoclonal antibody designed to address the underlying drivers of inflammation in HS. This multi-center, double-blind, randomized, placebo-controlled study will involve 96 participants over a 12-week duration.
Innovative Approach with CIT-013
CIT-013 utilizes a novel mechanism to target Extracellular Traps (ETs), which play an essential role in the inflammatory process associated with HS. This treatment aims to enhance the clearance of existing ETs while inhibiting the formation of new traps. Such an approach may offer a breakthrough in managing HS, a condition where current therapies often fall short.
Expert Guidance and Collaboration
Citryll has established a Clinical Advisory Board comprising renowned experts in dermatology to ensure the trial's success. This board includes distinguished professionals from leading institutions, such as Dr. James Krueger from The Rockefeller University and Dr. Alexa Kimbal from Harvard Medical School, who will provide strategic guidance throughout the trial.
Significance of the Trial
Chief Medical Officer Maarten Kraan expressed enthusiasm about this trial, highlighting the collaborative efforts paving the way for new treatment options for HS patients. Dr. Falk Bechara, the lead investigator, added that this trial represents a critical step toward delivering effective solutions for those suffering from this debilitating condition.
About Citryll and Its Mission
Citryll is committed to advancing treatments for immune-mediated inflammatory diseases, particularly through the innovative targeting of ETs. The company aims to pioneer a new class of therapies that could fundamentally change the treatment landscape for these conditions.
Contact Information
If you are seeking more information about Citryll or its clinical trials, you can reach out via email to info@citryll.com.
Frequently Asked Questions
What is the purpose of Citryll's Phase IIa trial?
The trial aims to evaluate the efficacy, safety, and tolerability of the monoclonal antibody CIT-013 in patients with hidradenitis suppurativa.
Who are the experts on Citryll’s Clinical Advisory Board?
The board includes distinguished figures like Dr. James Krueger and Dr. Alexa Kimbal, providing guidance on the trial's strategic direction.
How does CIT-013 work?
CIT-013 targets Extracellular Traps, enhancing the clearance of existing traps and preventing the formation of new ones, potentially improving disease management.
What are the potential benefits of the Citylights trial?
This trial could lead to new, effective treatments for patients suffering from a severe and painful condition with limited existing options.
How can I learn more about Citryll and its research?
For further inquiries, you can contact Citryll at their email, which is available on their official communication channels.
